<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01535209</url>
  </required_header>
  <id_info>
    <org_study_id>CAVITY</org_study_id>
    <nct_id>NCT01535209</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection</brief_title>
  <official_title>Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lower Silesian Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copernicus Memorial Hospital in Lodz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Centre - prof. Franciszek Łukaszczyk Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology</source>
  <oversight_info>
    <authority>Poland: Ministry of Science and Higher Education</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant whole-brain radiation therapy (WBRT) after resection of single brain metastasis is
      considered as a standard associated with side effects leading to decreased neurocognitive
      function. The Investigators addressed the question whether stereotactic radiotherapy of the
      resection cavity impairs neurological status and/or cognitive functions in compare to
      adjuvant WBRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with surgically removed single brain metastasis are randomly allocated to control
      or experimental arm. Before treatment the MRC Neurological Status Scale is used for
      assessing neurological status, the EORTC QLQ-C30 and QLQ-BN20 for quality of life and
      Mini-Mental State Examination to assess cognitive functioning. The control group receive
      30Gy in 10 fractions of 3Gy over 12 days to the whole brain. The patients in the
      experimental arm are treated with stereotactic radiotherapy to the resection cavity. The
      dose to the tumor bed is 15-18Gy in one fraction or 25Gy in 5 fractions. The study
      hypothesis is that the difference in the 5-months failure free survival rate isn't higher
      than 25% in experimental arm compared to control arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>5 months after radiotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to decrease in MRC scale by 1 point or in MMSE by 3 points or neurologic death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant intracranial progression</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local progression</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to progression in the irradiated cavity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>SBRT to resection cavity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18Gy in 1 fraction for resection cavity &lt;2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity &gt;4cm in maximum diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30Gy in 10 fractions over 12 days to whole brain</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiotherapy (SBRT)</intervention_name>
    <description>18Gy in 1 fraction for resection cavity &lt;2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity &gt;4cm in maximum diameter</description>
    <arm_group_label>SBRT to resection cavity</arm_group_label>
    <other_name>stereotactic body radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-Brain Radiotherapy (WBRT)</intervention_name>
    <description>10 x 3 Gy to whole brain</description>
    <arm_group_label>WBRT</arm_group_label>
    <other_name>whole brain irradiation</other_name>
    <other_name>adjuvant cranial irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with surgically removed histologically proven metastatic cancer

          -  Subtotal or total resection of single brain metastasis

          -  Presence of single brain metastasis in MRI

          -  Karnofsky Performance Status ≥ 70

          -  Life expectancy &gt; 6 months (minimal extracranial disease or availability of effective
             oncology treatment)

          -  No previous history of cranial irradiation

          -  Availability of MRI

          -  Starting radiotherapy within six weeks after neurosurgery

          -  Negative pregnancy test for woman

          -  Written informed consent

        Exclusion Criteria:

          -  Dementia and central nervous system diseases leading to higher risk of radiation
             toxicity

          -  Contraindications for MRI and/or no patient's tolerance and acceptance of cranial MRI

          -  Altered level of consciousness

          -  Histologically proven metastatic small cell lung cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucyna Kepka, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Michalski, M.S.</last_name>
    <phone>+48226433909</phone>
    <email>W.Michalski@coi.waw.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>M.Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucyna Kepka, Prof.</last_name>
      <phone>+48226439287</phone>
      <email>lucynak@coi.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Lucyna Kepka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 16, 2012</lastchanged_date>
  <firstreceived_date>February 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiotherapy</keyword>
  <keyword>Whole-brain radiotherapy</keyword>
  <keyword>Resection cavity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
